SAN RAFAEL, Calif.,
Oct. 1, 2019 /PRNewswire/ -- BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN) today announced that
Robert Baffi, Ph.D., President of
Global Manufacturing and Technical Operations, will participate in
a fireside discussion at the Jefferies Gene Therapy/Editing Summit
on October 8, 2019 at 11:15am ET in New York. Dr. Baffi will also
participate in the panel discussion on manufacturing, dose, and
durability in gene therapy at 10:20am
ET, which will not be available by webcast.
To access the live webcast presentation, please visit the
investor section of the BioMarin website, www.biomarin.com. A
replay will also be archived on the site for at least one week
following each event.
About BioMarin
BioMarin is a global biotechnology
company that develops and commercializes innovative therapies for
people with serious and life-threatening rare disorders. The
company's portfolio consists of seven commercialized products and
multiple clinical and pre-clinical product
candidates.
For additional information, please visit www.biomarin.com.
Information on BioMarin's website is not incorporated by reference
into this press release.
|
Contacts:
|
|
|
Investors
|
Media
|
|
Traci
McCarty
|
Debra
Charlesworth
|
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
|
(415)
455-7558
|
(415)
455-7451
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-jefferies-gene-therapyediting-summit-on-october-8-2019-in-new-york-300928381.html
SOURCE BioMarin Pharmaceutical Inc.